Some current partnerships
Our current partners and clients range from start-ups and SMEs to global pharmaceutical companies. Collaborations with School researchers span studies into mechanisms underlying disease through to full-scale clinical trials. Many of these projects have resulted in long-term partnerships. We have worked with over 100 companies in the last 10 years. See below for some of our current partnerships.
The School of Medicine currently leads over 100 clinical trials in partnership with pharmaceutical and biotech companies. Examples include assessing treatments for joint pain, skin conditions, gut and liver disorders, hearing loss, tinnitus, multiple sclerosis, stroke, asthma and cystic fibrosis.
Dedicated facilities for clinical research and Phase I-III Trials are available across our units including the NIHR Nottingham Biomedical Research Centre, the Sir Peter Mansfield Imaging Centre, the Arthritis Research UK Pain Centre, the Nottingham Clinical Trials Unit and the Clinical Research Facility.
Ex Vivo Cancer Pharmacology Centre of Excellence
The Ex Vivo Cancer Pharmacology Centre of Excellence was opened in March 2010 with a multi-million pound research grant from Janssen Pharmaceutica NV. The centre is developing patient-relevant models that accurately predict clinical efficacy of a new range of anti-cancer drugs to reduce the number which fail in human clinical trials.
Research developments within our school can also be accessed through our spin-out, PRECOS.
In March 2011, UK Health Secretary Andrew Lansley visited the Nottingham Digestive Diseases Biomedical Research Unit to learn how £13.5M follow-up investment from National Institute for Health Research (NIHR) to Nottingham University Hospitals Trust and the School of Medicine would further boost GI tract therapies.
The school currently has more than 20 industrial partners in this area.
Visit the GI and Liver Diseases research group.
Studies into the genetic basis of chronic lung disease are being accelerated by multi-million pound investment from Pfizer and AstraZeneca and collaboration with Nottingham based sequencing company, Source Bioscience. We currently run 12 clinical trials for asthma, lung fibrosis and cystic fibrosis with a range of industrial partners. Mologic, Novartis and GlaxoSmithKline are amongst the sponsors of our PhD programmes.
Visit the Respiratory Research group.
Richard Lambert, former Director-General of the Confederation of British Industry opened the Centre for Biomolecular Sciences, housing the largest dedicated stem cell culture suite in a UK University. Scientists from our school are working with Syngenta and Stem Cells for Safer Medicines to automate human pluripotent stem cells and their caridiomyocyte/ hepatocyte derivatives for high throughput screening.
Stem cell clinical trials/studies include those for stroke, Crohn’s disease, multiple sclerosis, corneal regeneration and bone repair and involve, for example, ReNeuron, & Epistem.
Visit the Stem Cell Biology group.
Thrombosis and Haemostasis
Combining research programmes using tools from deCODE genetics and ONO Pharmaceuticals and clinical trials relevant to platelet function undertaken with GSK and AstraZeneca, we strive to improve prevention and treatment of atherosclerosis.
Our spin-out, Platelet Solutions, adds to the portfolio of industrially-relevant R&D undertaken by our researchers.
[Back to Top]